1	Effect	Effect	B-NP	NN	O	15	NMOD	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	thalidomide	thalidomide	B-NP	NN	O	2	PMOD	0
4	affecting	affect	B-VP	VBG	O	3	NMOD	16	affecting
5	VEGF	VEGF	B-NP	NN	B-protein	6	NMOD	0
6	secretion	secretion	I-NP	NN	O	4	OBJ	14	secretion
7	,	,	O	,	O	15	P	0
8	cell	cell	B-NP	NN	O	9	NMOD	0
9	migration	migration	I-NP	NN	O	15	NMOD	0
10	,	,	O	,	O	15	P	0
11	adhesion	adhesion	B-NP	NN	O	15	NMOD	15	adhesion
12	and	and	O	CC	O	15	NMOD	0
13	capillary	capillary	B-NP	JJ	O	15	NMOD	0
14	tube	tube	I-NP	NN	O	15	NMOD	0
15	formation	formation	I-NP	NN	O	0	ROOT	2	formation
16	of	of	B-PP	IN	O	15	NMOD	0
17	human	human	B-NP	JJ	B-cell_line	21	NMOD	0
18	endothelial	endothelial	I-NP	JJ	I-cell_line	21	NMOD	0
19	EA.hy	EA.hy	I-NP	NNP	I-cell_line	21	NMOD	0
20	926	926	I-NP	CD	I-cell_line	21	NMOD	0
21	cells	cell	I-NP	NNS	I-cell_line	16	PMOD	0
22	.	.	O	.	O	15	P	0

1	Angiogenesis	Angiogenesis	B-NP	NN	O	6	NMOD	3	Angiogenesis
2	,	,	O	,	O	6	P	0
3	new	new	B-NP	JJ	O	6	NMOD	0
4	blood	blood	I-NP	NN	O	6	NMOD	0
5	vessel	vessel	I-NP	NN	O	6	NMOD	0
6	formation	formation	I-NP	NN	O	8	SUB	2	formation
7	,	,	O	,	O	6	P	0
8	is	be	B-VP	VBZ	O	0	ROOT	0
9	a	a	B-NP	DT	O	11	NMOD	0
10	multistep	multistep	I-NP	JJ	O	11	NMOD	0
11	process	process	I-NP	NN	O	8	PRD	0
12	,	,	O	,	O	11	P	0
13	precisely	precisely	B-VP	RB	O	14	VMOD	0
14	regulated	regulate	I-VP	VBN	O	11	NMOD	16	regulated
15	by	by	B-PP	IN	O	14	VMOD	0
16	pro-angiogenic	pro-angiogenic	B-NP	JJ	B-protein	17	NMOD	3	angiogenic
17	cytokines	cytokine	I-NP	NNS	I-protein	15	PMOD	0
18	,	,	O	,	O	17	P	0
19	which	which	B-NP	WDT	O	17	NMOD	0
20	stimulate	stimulate	B-VP	VBP	O	19	SBAR	17	stimulate
21	endothelial	endothelial	B-NP	JJ	B-cell_type	22	NMOD	0
22	cells	cell	I-NP	NNS	I-cell_type	20	OBJ	0
23	to	to	B-VP	TO	O	24	VMOD	0
24	migrate	migrate	I-VP	VB	O	20	VMOD	14	migrate
25	,	,	I-VP	,	O	20	P	0
26	proliferate	proliferate	I-VP	VB	O	20	VMOD	1	proliferate
27	and	and	O	CC	O	20	VMOD	0
28	differentiate	differentiate	B-VP	VB	O	20	VMOD	2	differentiate
29	to	to	I-VP	TO	O	30	VMOD	0
30	form	form	I-VP	VB	O	28	VMOD	2	form
31	new	new	B-NP	JJ	O	33	NMOD	0
32	capillary	capillary	I-NP	JJ	O	33	NMOD	0
33	microvessels	microvessel	I-NP	NNS	O	30	OBJ	0
34	.	.	O	.	O	8	P	0

1	Excessive	Excessive	B-NP	JJ	O	3	NMOD	0
2	vascular	vascular	I-NP	JJ	O	3	NMOD	0
3	development	development	I-NP	NN	O	7	NMOD	2	development
4	and	and	O	CC	O	7	NMOD	0
5	blood	blood	B-NP	NN	O	7	NMOD	0
6	vessel	vessel	I-NP	NN	O	7	NMOD	0
7	remodeling	remodeling	I-NP	NN	O	8	SUB	7	remodeling
8	appears	appear	B-VP	VBZ	O	0	ROOT	0
9	in	in	B-PP	IN	O	8	VMOD	0
10	psoriasis	psoriasis	B-NP	NN	O	20	NMOD	0
11	,	,	O	,	O	20	P	0
12	rheumatoid	rheumatoid	B-NP	JJ	O	13	NMOD	0
13	arthritis	arthritis	I-NP	NN	O	20	NMOD	0
14	,	,	O	,	O	20	P	0
15	diabetic	diabetic	B-NP	JJ	O	16	NMOD	0
16	retinopathy	retinopathy	I-NP	NN	O	20	NMOD	0
17	and	and	O	CC	O	20	NMOD	0
18	solid	solid	B-NP	JJ	O	20	NMOD	0
19	tumors	tumor	I-NP	NNS	O	20	NMOD	0
20	formation	formation	I-NP	NN	O	9	PMOD	2	formation
21	.	.	O	.	O	8	P	0

1	Thalidomide	Thalidomide	B-NP	NN	O	9	SUB	0
2	[	[	O	(	O	8	DEP	0
3	alpha-	alpha-	B-NP	NN	O	7	NMOD	0
4	(	(	O	(	O	6	DEP	0
5	N-phthalimido	N-phthalimido	B-NP	NN	O	6	DEP	0
6	)	)	O	)	O	7	NMOD	0
7	-glutarimide	-glutarimide	B-NP	NN	O	8	DEP	0
8	]	]	O	)	O	1	NMOD	0
9	is	be	B-VP	VBZ	O	26	VMOD	0
10	known	know	I-VP	VBN	O	9	VC	0
11	to	to	I-VP	TO	O	12	VMOD	0
12	be	be	I-VP	VB	O	10	VMOD	0
13	a	a	B-NP	DT	O	15	NMOD	0
14	potent	potent	I-NP	JJ	O	15	NMOD	0
15	inhibitor	inhibitor	I-NP	NN	O	12	PRD	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	angiogenesis	angiogenesis	B-NP	NN	O	16	PMOD	3	angiogenesis
18	,	,	O	,	O	26	P	0
19	but	but	O	CC	O	26	VMOD	0
20	the	the	B-NP	DT	O	21	NMOD	0
21	mechanism	mechanism	I-NP	NN	O	26	SUB	0
22	of	of	B-PP	IN	O	21	NMOD	0
23	its	its	B-NP	PRP$	O	25	NMOD	0
24	inhibitory	inhibitory	I-NP	JJ	O	25	NMOD	0
25	action	action	I-NP	NN	O	22	PMOD	0
26	remains	remain	B-VP	VBZ	O	0	ROOT	0
27	unclear	unclear	B-ADJP	JJ	O	26	PRD	0
28	.	.	O	.	O	26	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	aim	aim	I-NP	NN	O	6	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	the	the	B-NP	DT	O	5	NMOD	0
5	study	study	I-NP	NN	O	3	PMOD	0
6	was	be	B-VP	VBD	O	0	ROOT	0
7	to	to	B-VP	TO	O	8	VMOD	0
8	investigate	investigate	I-VP	VB	O	6	PRD	0
9	the	the	B-NP	DT	O	11	NMOD	0
10	potential	potential	I-NP	JJ	O	11	NMOD	0
11	influence	influence	I-NP	NN	O	8	OBJ	16	influence
12	of	of	B-PP	IN	O	11	NMOD	0
13	thalidomide	thalidomide	B-NP	NN	O	12	PMOD	0
14	on	on	B-PP	IN	O	11	NMOD	0
15	the	the	B-NP	DT	O	17	NMOD	0
16	several	several	I-NP	JJ	O	17	NMOD	0
17	steps	step	I-NP	NNS	O	14	PMOD	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	angiogenesis	angiogenesis	B-NP	NN	O	18	PMOD	3	angiogenesis
20	,	,	O	,	O	8	P	0
21	using	use	B-VP	VBG	O	8	VMOD	0
22	in	in	B-NP	FW	O	23	AMOD	0
23	vitro	vitro	I-NP	FW	O	24	NMOD	0
24	models	model	I-NP	NNS	O	21	OBJ	0
25	.	.	O	.	O	6	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	have	have	B-VP	VBP	O	0	ROOT	0
3	evaluated	evaluate	I-VP	VBN	O	2	VC	0
4	the	the	B-NP	DT	O	5	NMOD	0
5	effect	effect	I-NP	NN	O	15	NMOD	16	effect
6	of	of	B-PP	IN	O	5	NMOD	0
7	thalidomide	thalidomide	B-NP	NN	O	6	PMOD	0
8	on	on	B-PP	IN	O	5	NMOD	0
9	VEGF	VEGF	B-NP	NN	B-protein	10	NMOD	0
10	secretion	secretion	I-NP	NN	O	8	PMOD	14	secretion
11	,	,	O	,	O	15	P	0
12	cell	cell	B-NP	NN	O	13	NMOD	0
13	migration	migration	I-NP	NN	O	15	NMOD	0
14	,	,	O	,	O	15	P	0
15	adhesion	adhesion	B-NP	NN	O	3	OBJ	15	adhesion
16	as	as	B-CONJP	RB	O	15	NMOD	0
17	well	well	I-CONJP	RB	O	16	DEP	0
18	as	as	I-CONJP	IN	O	16	DEP	0
19	in	in	B-PP	IN	O	16	PMOD	0
20	capillary	capillary	B-NP	JJ	O	21	NMOD	0
21	formation	formation	I-NP	NN	O	19	PMOD	2	formation
22	of	of	B-PP	IN	O	21	NMOD	0
23	human	human	B-NP	JJ	B-cell_line	26	NMOD	0
24	endothelial	endothelial	I-NP	JJ	I-cell_line	26	NMOD	0
25	cell	cell	I-NP	NN	I-cell_line	26	NMOD	0
26	line	line	I-NP	NN	I-cell_line	28	NMOD	0
27	EA.hy	EA.hy	B-NP	NNP	O	28	NMOD	0
28	926	926	I-NP	CD	O	22	PMOD	0
29	.	.	O	.	O	2	P	0

1	Thalidomide	Thalidomide	B-NP	NN	O	11	SUB	0
2	at	at	B-PP	IN	O	1	NMOD	0
3	the	the	B-NP	DT	O	4	NMOD	0
4	concentrations	concentration	I-NP	NNS	O	2	PMOD	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	0.01	0.01	B-NP	CD	O	7	NMOD	0
7	microM	microM	I-NP	NN	O	10	NMOD	0
8	and	and	O	CC	O	10	NMOD	0
9	10	10	B-NP	CD	O	10	NMOD	0
10	microM	microM	I-NP	NN	O	5	PMOD	0
11	inhibited	inhibit	B-VP	VBD	O	0	ROOT	18	inhibited
12	VEGF	VEGF	B-NP	NN	B-protein	13	NMOD	0
13	secretion	secretion	I-NP	NN	O	11	OBJ	14	secretion
14	into	into	B-PP	IN	O	13	NMOD	0
15	supernatants	supernatant	B-NP	NNS	O	14	PMOD	0
16	,	,	O	,	O	11	P	0
17	decreased	decrease	B-VP	VBD	O	11	VMOD	18	decreased
18	the	the	B-NP	DT	O	19	NMOD	0
19	number	number	I-NP	NN	O	17	OBJ	0
20	of	of	B-PP	IN	O	19	NMOD	0
21	formed	form	B-NP	VBN	O	23	NMOD	2	formed
22	capillary	capillary	I-NP	JJ	O	23	NMOD	0
23	tubes	tube	I-NP	NNS	O	20	PMOD	0
24	and	and	O	CC	O	17	VMOD	0
25	increased	increase	B-NP	VBN	O	17	VMOD	17	increased
26	cell	cell	I-NP	NN	O	27	NMOD	0
27	adhesion	adhesion	I-NP	NN	O	25	OBJ	15	adhesion
28	to	to	B-PP	TO	O	27	NMOD	0
29	collagen	collagen	B-NP	NN	B-protein	28	PMOD	0
30	.	.	O	.	O	11	P	0

1	Administration	Administration	B-NP	NN	O	10	SUB	19	Administration
2	of	of	B-PP	IN	O	1	NMOD	0
3	thalidomide	thalidomide	B-NP	NN	O	2	PMOD	0
4	at	at	B-PP	IN	O	1	NMOD	0
5	the	the	B-NP	DT	O	6	NMOD	0
6	concentration	concentration	I-NP	NN	O	4	PMOD	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	0.01	0.01	B-NP	CD	O	9	NMOD	0
9	microM	microM	I-NP	NN	O	7	PMOD	0
10	increased	increase	B-VP	VBD	O	0	ROOT	17	increased
11	cell	cell	B-NP	NN	O	12	NMOD	0
12	migration	migration	I-NP	NN	O	10	OBJ	14	migration
13	,	,	O	,	O	10	P	0
14	while	while	B-SBAR	IN	O	10	VMOD	0
15	at	at	B-PP	IN	O	14	DEP	0
16	10	10	B-NP	CD	O	17	NMOD	0
17	microM	microM	I-NP	NN	O	15	PMOD	0
18	,	,	O	,	O	10	P	0
19	it	it	B-NP	PRP	O	20	SUB	0
20	decreased	decrease	B-VP	VBD	O	10	VMOD	18	decreased
21	cell	cell	B-NP	NN	O	22	NMOD	0
22	migration	migration	I-NP	NN	O	20	OBJ	14	migration
23	.	.	O	.	O	10	P	0

1	Thalidomide	Thalidomide	B-NP	NN	O	10	SUB	0
2	in	in	B-PP	IN	O	1	NMOD	0
3	concentrations	concentration	B-NP	NNS	O	2	PMOD	0
4	from	from	B-PP	IN	O	3	NMOD	0
5	0.1	0.1	B-NP	CD	O	6	NMOD	0
6	microM	microM	I-NP	NN	O	4	PMOD	0
7	to	to	B-PP	TO	O	3	NMOD	0
8	10	10	B-NP	CD	O	9	NMOD	0
9	microM	microM	I-NP	NN	O	7	PMOD	0
10	did	do	B-VP	VBD	O	0	ROOT	0
11	not	not	I-VP	RB	O	10	VMOD	0
12	change	change	I-VP	VB	O	10	VC	16	change
13	cell	cell	B-NP	NN	O	14	NMOD	0
14	proliferation	proliferation	I-NP	NN	O	12	OBJ	1	proliferation
15	of	of	B-PP	IN	O	14	NMOD	0
16	72-h	72-h	B-NP	JJ	B-cell_line	18	NMOD	0
17	cell	cell	I-NP	NN	I-cell_line	18	NMOD	0
18	cultures	culture	I-NP	NNS	I-cell_line	15	PMOD	0
19	.	.	O	.	O	10	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	conclude	conclude	B-VP	VBP	O	0	ROOT	0
3	that	that	B-SBAR	IN	O	2	VMOD	0
4	anti-angiogenic	anti-angiogenic	B-NP	JJ	O	5	NMOD	3	angiogenic
5	action	action	I-NP	NN	O	8	SUB	18	action
6	of	of	B-PP	IN	O	5	NMOD	0
7	thalidomide	thalidomide	B-NP	NN	O	6	PMOD	0
8	is	be	B-VP	VBZ	O	3	SBAR	0
9	due	due	B-ADJP	JJ	O	8	PRD	17	due
10	to	to	B-VP	TO	O	11	VMOD	0
11	direct	direct	I-VP	VB	O	9	AMOD	0
12	inhibitory	inhibitory	B-NP	JJ	O	13	NMOD	0
13	action	action	I-NP	NN	O	11	OBJ	0
14	on	on	B-PP	IN	O	13	NMOD	0
15	VEGF	VEGF	B-NP	NN	B-protein	16	NMOD	0
16	secretion	secretion	I-NP	NN	O	20	NMOD	14	secretion
17	and	and	O	CC	O	20	NMOD	0
18	capillary	capillary	B-NP	JJ	O	20	NMOD	0
19	microvessel	microvessel	I-NP	NN	O	20	NMOD	0
20	formation	formation	I-NP	NN	O	14	PMOD	2	formation
21	as	as	B-CONJP	RB	O	25	NMOD	0
22	well	well	I-CONJP	RB	O	21	DEP	0
23	as	as	I-CONJP	IN	O	21	DEP	0
24	immunomodulatory	immunomodulatory	B-NP	JJ	O	25	NMOD	0
25	influence	influence	I-NP	NN	O	11	OBJ	16	influence
26	on	on	B-PP	IN	O	25	NMOD	0
27	EA.hy	EA.hy	B-NP	NNP	O	29	NMOD	0
28	926	926	I-NP	CD	O	29	NMOD	0
29	cells	cell	I-NP	NNS	O	32	NMOD	0
30	migration	migration	B-NP	NN	O	32	NMOD	14	migration
31	and	and	I-NP	CC	O	32	NMOD	0
32	adhesion	adhesion	I-NP	NN	O	26	PMOD	15	adhesion
33	.	.	O	.	O	2	P	0

